SETD2 and cancer: To investigate whether SETD2 exacerbates SMAD4‐dificiency CRC, we first consulted the clinical data samples of CRC in the TCGA database and analysed the expression levels of SETD2 and SMAD4 in the samples of CRC patients and their relationship with cancer stage and survival rate.